ComboMATCH Treatment Trials
ComboMATCH is a large precision medicine initiative with a coordinated set of clinical trials evaluating new anti-cancer drug combinations in select groups of adults and children with cancer. Each trial studies the effectiveness of a specific drug combination in a select group of patients (called a phase 2 trial design). The drug combinations are either two targeted therapies or chemotherapy with a targeted drug. Targeted therapy is a type of cancer treatment that targets the changes in cancer cells that cause them to grow, divide, and spread.
Generally, this set of trials is for patients with advanced solid tumors. However, each trial has its own patient inclusion and exclusion criteria, such as the targeted tumor gene abnormalities, type of cancer, stage of disease, prior treatment, age of the patient, etc. Therefore, patients must first enroll in the ComboMATCH Patient Registration Trial (EAY191) for a screening assessment to help determine eligibility for a treatment trial.
Treatment Trials
Nine treatment trials are planned for ComboMATCH, opening to patient enrollment on a rolling basis. ComboMATCH is an exciting system-wide collaboration. The Alliance for Clinical Trials in Oncology, Children's Oncology Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, and SWOG Cancer Research Network lead the various treatment trials with funding from the National Cancer Institute through its National Clinical Trials Network (NCTN).
To learn more about a particular treatment trial, click the Trial ID in the table below. These links will open the federal trial record. Hover over column headings and click the up/down arrows to sort the table. You can also search by keyword.
| Drug Combination / Molecular Target(s) | Trial ID / Lead Group | Status |
|---|---|---|
| Fulvestrant hormonal therapy & binimetinib in hormone receptor positive (HR+) breast cancers with NF1 mutation or NF1 whole gene deletion | EAY191-N2 NRG Oncology | Active |
| Chemotherapy & binimetinib in RAS, RAF, MEK, ERK mutations | EAY191-A6 Alliance | In Review |
| Paclitaxel chemotherapy & ipatasertib in AKT mutations | EAY191-S3 SWOG | Active |
| Nilotinib & paclitaxel chemotherapy in tumors previously treated with taxane chemotherapy | EAY191-E4 ECOG-ACRIN | Active |
| Olaparib & alpelisib in various abnormalities | EAY191-A2 Link to Come Alliance | In Review |
| Palbociclib & binimetinib in RAS mutations | EAY191-A3 Alliance | In Review |
| Selumetinib & DAY101 | EAY191-C1 Link to Come Childrens' Oncology | In Review |
| Selumetinib & olaparib in RAS pathway mutations | EAY191-N4 NRG Oncology | Active |
| Sotorasib & panitumumab in KRAS G12C mutations | EAY191-E5 ECOG-ACRIN | In Review |
Questions?
- Patients interested in learning more about ComboMATCH should start by speaking with their doctor or healthcare team
- Reach out to the Contact Center at the National Cancer Institute, where trained specialists answer cancer-related questions in English and Spanish
- Study personnel with questions about ComboMATCH may send an email to the National Cancer Institute